Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RU-486 "approvable" decision occurs on Sept. 18 user fee deadline.

Executive Summary

RU-486 DECISION DEADLINE COINCIDES WITH CONGRESSIONAL DEBATE on President Clinton's veto of a ban on partial birth abortions. The confluence of FDA's publicly stated Sept. 18 deadline for a decision on the abortifacient and the Congressional attention to the veto gave political resonance to FDA's decision to grant "approvable status" to mifepristone. Following the advisory committee review of mifepristone in July, FDA Commissioner Kessler declared the agency would make a decision by the six-month user fee deadline of Sept. 18 ("The Pink Sheet" July 22, p. 3).

You may also be interested in...



FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization

Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Latest News
See All
UsernamePublicRestriction

Register

PS028906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel